Patent ID: 9359633
Filing Date: 2016-06-07
CPC Classification: C07K,C12Q,G01N

Claim Text:
1. A method of diagnosis or of quantitation of cardiovascular disease comprising; obtaining a patient biofluid sample, conducting an immunoassay to measure fragments of collagen type III comprising an N- or C-terminal neo-epitope formed by cleavage of collagen type III by MMP-1, MMP-2, MMP-3, MMP-8, MMP-9, MMP-13, ADAMTS-5, CathepsinK, CathepsinS, ADAMTS1, ADAMTS4 or ADAMTS8, said fragments being naturally present in a said biofluid sample, and associating an elevation of said measure in said patient above a normal level with the presence or extent of cardiovascular disease, wherein said bioassay immunoassay is conducted by a method comprising: contacting the fragments of collagen type III having said N- or C-terminal neo-epitope that are naturally present in said sample with an immunological binding partner specifically reactive with the N-terminal or C-terminal neo-epitope, but not reactive with intact collagen type III, and, measuring the extent of binding of the N- or C-terminal neo-epitope to said immunological binding partner to measure therein fragments comprising said neo-epitope; wherein said immunological binding partner is raised against a synthetic peptide corresponding to an N- or C-terminal neo epitope amino acid sequence formed by cleavage of the collagen type III by MMP-1, MMP-2, MMP-3, MMP-8, MMP-9, MMP-13, ADAMTS5, CathepsinK, CathepsinS, ADAMTS1, ADAMTS4 or ADAMTS8 and specifically binds a neo-epitope constituted by said N- or C-terminal amino acid sequence, said N-terminal amino acid sequence selected from the group consisting of any sequence directly following the sign * in any one the following sequences or said C-terminal amino acid sequence selected from the group consisting of any sequence directly preceding the sign * in any one of the following sequences: